AnnaPalmerDurbinMD

Infectious Disease • Baltimore, MD

Associate Professor

Join to view full profile

Dr. Durbin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Durbin's full profile

Already have an account?

Office
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
Phone+1 410-955-1725
Is this information wrong?

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Infectious Disease, 1991 - 1994
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 1987 - 1991
Wayne State University School of MedicineClass of 1987

Certifications & Licensure

MD State Medical License 1994 - 2024
MI State Medical License 1983 - 2015
DC State Medical License 2006 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults Start of enrollment: 2004 Sep 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults Start of enrollment: 2005 Jan 01
Completed
Phase 1
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults Start of enrollment: 2005 Feb 01
Completed
Phase 1
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Start of enrollment: 2005 Jul 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults Start of enrollment: 2006 Jun 01
Completed
Phase 1
Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant Start of enrollment: 2006 Mar 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults Start of enrollment: 2007 Jan 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Start of enrollment: 2006 Oct 01
Completed
Phase 1
Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Start of enrollment: 2007 Mar 01
Completed
Phase 1
Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine Start of enrollment: 2007 May 01
Completed
Phase 1
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults Start of enrollment: 2008 Mar 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults Start of enrollment: 2008 Dec 01
Completed
Phase 1
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults Start of enrollment: 2009 Sep 01
Completed
Phase 1
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus Start of enrollment: 2009 Jul 01
Completed
Phase 1
Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine Start of enrollment: 2009 Jan 01
Completed
Phase 1
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine Start of enrollment: 2010 Jul 01
Completed
Phase 1
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Start of enrollment: 2010 Apr 01
Completed
Phase 1
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Start of enrollment: 2011 Aug 01
Completed
Phase 1
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Start of enrollment: 2011 Dec 01
Completed
Phase 1
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart Start of enrollment: 2013 Jan 01
Completed
Phase 1
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults Start of enrollment: 2013 Jun 01
Completed
Phase 1
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults Start of enrollment: 2013 Nov 01
Completed
Phase 1
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age Start of enrollment: 2014 Feb 01
Completed
Phase 1
Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge Start of enrollment: 2017 Nov 28
Completed
Phase 1
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) Start of enrollment: 2022 Feb 16
Recruiting
Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Promising efforts to develop an mRNA vaccine against Zika.
Annelies Wilder-Smith, Anna Durbin> ;The Lancet. Infectious Diseases. 2023 May 1
82 citations
Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response
Carleigh B. Krubiner, Ruth R. Faden, Ruth A. Karron, Margaret Olivia Little, Anne Drapkin Lyerly, Jon S. Abramson, Richard H. Beigi, Alejandro Cravioto, Anna P. Durbin...> ;Vaccine. 2021 Jan 3
6 citations
Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003.
Huy A. Tu, Usha K. Nivarthi, Nancy R. Graham, Philip Eisenhauer, Matthew J. Delacruz, Kristen K. Pierce, Stephen S. Whitehead, Jonathan E. Boyson, Jason Botten, Beth D...> ;Cell Reports. Medicine. 2020 Dec 22
36 citations
Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees
David R. Martinez, Boyd Yount, Usha K. Nivarthi, Jennifer E. Munt, Matthew J. Delacruz, Stephen S. Whitehead, Anna P. Durbin, Aravinda M. de Silva, Ralph S. Baric> ;Cell Reports. 2020 Oct 6
13 citations
Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers
Myron M. Levine, Salim Abdullah, Yaseen M. Arabi, Delese Mimi Darko, Anna P. Durbin, Vicente Estrada, Euzebiusz Jamrozik, Peter G. Kremsner, Rosanna Lagos, Punnee Piti...> ;Clinical Infectious Diseases. 2021 Jun 1
16 citations
Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005
Anna P. Durbin> ;Current Opinion in Virology. 2020 Aug 1
34 citations
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled p...
Esper G. Kallas, Alexander Roberto Precioso, Ricardo Palacios, Beatriz Thomé, Patrícia Emília Braga, Tazio Vanni, Lucia M.A. Campos, Lilian Ferrari, Gabriela Mondini, ...> ;The Lancet. Infectious Diseases. 2020 Mar 24
13 citations
Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report.
Andrew J. Pollard, Robert W. Sauerwein, Marc Baay, Pieter Neels, Hct speakers, Shobana Balasingam, Philip Bejon, N Berthels, Susan Bull, A Catchpole, Primus Che Chi, R...> ;Biologicals. 2020 Jun 3
10 citations
Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Result...
Anna P. Durbin, Kristen K. Pierce, Beth D. Kirkpatrick, Palmtama L. Grier, Beulah P. Sabundayo, Helen He, Michele Sausser, Amy Falk Russell, Jason C. Martin, Donna Hya...> ;The American Journal of Tropical Medicine and Hygiene. 2020 May 7
Corrigendum to ''Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model'' [EBioMedicine 41 (2019) 465-478].
Usha K. Nivarthi, Huy A. Tu, Matthew J. Delacruz, Jesica Swanstrom, Bhumi Patel, Anna P. Durbin, Stephen S. Whitehead, Kristen K. Pierce, Beth D. Kirkpatrick, Ralph S....> ;Ebiomedicine. 2020 Apr 1
27 citations
Rapid Induction and Maintenance of Virus-Specific CD8+ TEMRA and CD4+ TEM Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans.
Nancy R. Graham, Phil Eisenhauer, Sean A. Diehl, Kristen K. Pierce, Stephen S. Whitehead, Anna P. Durbin, Beth D. Kirkpatrick, Alessandro Sette, Daniela Weiskopf, Jona...> ;Frontiers in Immunology. 2020 Mar 24
44 citations
T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
Alba Grifoni, Hannah Voic, Sandeep Kumar Dhanda, Conner K. Kidd, James D. Brien, Søren Buus, Anette Stryhn, Anna P. Durbin, Stephen S. Whitehead, Sean A. Diehl, Aruna ...> ;Journal of Virology. 2020 May 4
23 citations
What is the prospect of a safe and effective dengue vaccine for travellers
Anna P. Durbin, Duane J. Gubler> ;Journal of Travel Medicine. 2019 Sep 2
33 citations
Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report.
Annelies Wilder-Smith, Pete Smith, R. Luo, Cassandra Kelly-Cirino, D. Curry, Heidi J. Larson, Anna P. Durbin, M. Chu, Piyanit Tharmaphornpilas, Lee Ching Ng, Ana Marli...> ;Vaccine. 2019 Aug 23
18 citations
Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
Jesica Swanstrom, Usha K. Nivarthi, Bhumi Patel, Matthew J. Delacruz, Boyd Yount, Douglas G. Widman, Anna P. Durbin, Stephen S. Whitehead, Aravinda M. de Silva, Ralph ...> ;The Journal of Infectious Diseases. 2019 Jun 19
21 citations
Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model.
Usha K. Nivarthi, Huy A. Tu, Matthew J. Delacruz, Jesica Swanstrom, Bhumi Patel, Anna P. Durbin, Stephen S. Whitehead, Kristen K. Pierce, Beth D. Kirkpatrick, Ralph S....> ;Ebiomedicine. 2019 Mar 1
42 citations
Cutting Edge:Transcriptional profiling reveals multifunctional and cytotoxic antiviral responses of zika virus-specific CD8 + T cells
Alba Grifoni, Priscilla Costa-Ramos, John Pham, Yuan Tian, Sandy L. Rosales, Grégory Seumois, John Sidney, Aruna D. De Silva, Lakshmanane Premkumar, Matthew H. Collins...> ;Journal of Immunology. 2018 Nov 9
10 citations
Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers.
Stephen J. Popper, Fiona R. Strouts, Janet C. Lindow, Henry K. Cheng, Magelda Montoya, Angel Balmaseda, Anna P. Durbin, Stephen S. Whitehead, Eva Harris, Beth D. Kirkp...> ;The Journal of Infectious Diseases. 2018 Nov 5
44 citations
Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.
Emily N. Gallichotte, Thomas J. Baric, Usha K. Nivarthi, Matthew J. Delacruz, Rachel L. Graham, Douglas G. Widman, Boyd Yount, Anna P. Durbin, Stephen S. Whitehead, Ar...> ;Cell Reports. 2018 Oct 30
80 citations
Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus
Leah C. Katzelnick, Ana Coello Escoto, Benjamin D. McElvany, Christian Chávez, Henrik Salje, Wensheng Luo, Isabel Rodriguez-Barraquer, Richard G. Jarman, Anna P. Durbi...> ;Plos Neglected Tropical Diseases. 2018 Oct 24
2 citations
Impact of Dengue Virus Serotype 2 Strain Diversity on Serological Immune Responses to Dengue.
Sarah L. Keasey, Jessica L. Smith, Stefan Fernandez, Anna P. Durbin, Bryan M. Zhao, Robert G. Ulrich> ;ACS Infectious Diseases. 2018 Oct 22
22 citations
Development of standard clinical endpoints for use in dengue interventional trials
Kay M. Tomashek, Bridget Wills, Lucy Chai See Lum, Lian F. Thomas, Anna P. Durbin, Yee Sin Leo, Norma de Bosch, Elsa Marina Rojas, Kim Hendrickx, Martin Erpicum, Liane...> ;Plos Neglected Tropical Diseases. 2018 Oct 4
57 citations
Zika vaccines and therapeutics: landscape analysis and challenges ahead
Annelies Wilder-Smith, Kirsten S. Vannice, Anna P. Durbin, Joachim Hombach, Stephen J. Thomas, Irani Thevarjan, Cameron P. Simmons> ;BMC Medicine. 2018 Jun 6
44 citations
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines
Kirsten S. Vannice, Annelies Wilder-Smith, Alan D.T. Barrett, Kalinka Carrijo, Marco Cavaleri, Aravinda M. de Silva, Anna P. Durbin, Tim Endy, Eva Harris, Bruce L. Inn...> ;Vaccine. 2018 Jun 7
28 citations
Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes
Emily N. Gallichotte, Thomas J. Baric, Boyd Yount, Douglas G. Widman, Anna P. Durbin, Steve S. Whitehead, Ralph S. Baric, Aravinda M. de Silva> ;Plos Pathogens. 2018 Feb 26
Join now to see all

Press Mentions

Another AIDS Vaccine Day, yet No Vaccine for AIDSMay 19th, 2023
Harvard University Requires up to Five Covid Punches for Personal SeparationMarch 11th, 2023
Harvard University Requires up to FIVE Covid Shots for Classroom InstructionMarch 10th, 2023
Join now to see all